VFH vs XBI
Vanguard Financials ETF vs SPDR S&P Biotech ETF
- • VFH has the lower expense ratio at 0.09% vs 0.35% for XBI.
- • VFH pays a higher dividend yield (1.52%).
Side-by-side metrics
| Metric | VFH | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.52% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $13.71B | $8.30B |
YTD return | -4.12% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.93 | 1.09 |
P/E ratio | 16.70 | — |
Last price | $126.85 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
VFH top holdings
| JPM | JPMorgan Chase & Co | 9.06% |
| BRK-B | Berkshire Hathaway Inc Class B | 7.99% |
| MA | Mastercard Inc Class A | 5.13% |
| V | Visa Inc Class A | 3.98% |
| BAC | Bank of America Corp | 3.85% |
| WFC | Wells Fargo & Co | 3.03% |
| GS | The Goldman Sachs Group Inc | 2.92% |
| MS | Morgan Stanley | 2.37% |
| C | Citigroup Inc | 2.31% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VFH
VFH (Vanguard Financials ETF) is US financial services sector stocks. Managed by Vanguard, the fund carries $13.7B in assets under management, an expense ratio of 0.09%, a dividend yield of 1.52%. Its largest holding is JPMorgan Chase & Co (JPM), which represents 9.1% of the portfolio. Real Estate is the fund's largest sector exposure at 0.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.